Antibody-Dependent Cellular Cytotoxicity (ADCC) is a primary mechanism for the action of therapeutic antibodies against cancer cells. Eureka's proprietary technology enhances the ADCC activity of therapeutic antibodies by utilizing the latest technology available in immunology and molecular cell biology. We possess a high-throughput, real-time, ADCC assay platform that facilitates and expedites the selection of antibody drug candidates.
Please contact technology@eurekainc.com for more details.